← Human Trials & Peer-Reviewed Studies
Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis
Plain-language guide to PMID 40551146 (2025): pilot observational study of BNP (Nesiritide) in 64 patients.
Key Facts
- PMID
- 40551146
- Journal
- BMC nephrology
- Year
- 2025
- Study type
- Observational Study
- Authors
- Svensson MK et al. (6 authors)
- DOI
- 10.1186/s12882-025-04251-8
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as an observational study.
The aim of this exploratory pilot study was to analyse the relationships between BNP, OH and all-cause mortality in patients with CKD and haemodialysis.
Why It Was Studied
Brain natriuretic peptide (BNP) is a hormone secreted from the heart in response to fluid overload.
In patients with chronic kidney disease (CKD), inadequate fluid management during haemodialysis may cause fluid overload and overhydration (OH), risk factors for mortality.
Who Took Part
According to the abstract, 64 patients were involved.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
In this prospective observational study, five-year survival was analysed in 64 patients with CKD and haemodialysis.
How the Study Was Run
In design terms this was a pilot study.
It is described as a pilot, a small early test of whether a larger BNP (Nesiritide) study would be practical.
Bivariate correlations were performed to analyse the relationships between BNP, OH, and all-cause mortality.
Cox regression analysis was performed to adjust the relationship between BNP and all-cause mortality for selected clinical and biochemical characteristics, collected at baseline.
What Was Measured
The subject headings attached to it are Renal Dialysis, Natriuretic Peptide, Brain, Renal Insufficiency, Chronic, Cause of Death, Pilot Projects, Biomarkers and Water-Electrolyte Imbalance.
Author keywords: Brain natriuretic peptide, Fluid overload, Haemodialysis and Survival analysis.
What This Means in Plain Language
The paper is a pilot study of BNP (Nesiritide) in 64 patients.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (BMC nephrology), a journal based in England.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.